| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | 0 |
Sells | $141,870,455 | 40 | 100 |
| Peng Katie | director | 0 | $0 | 1 | $34,627 | $-34,627 |
| Gilman Michael | director | 0 | $0 | 1 | $100,304 | $-100,304 |
| Reed Joshua | director | 0 | $0 | 1 | $160,463 | $-160,463 |
| Burow Kristina | director | 0 | $0 | 1 | $160,511 | $-160,511 |
| Brudnick Richard | director | 0 | $0 | 1 | $180,531 | $-180,531 |
| FLIER JEFFREY S. | director | 0 | $0 | 1 | $180,584 | $-180,584 |
| Vaishnaw Akshay | President of R&D | 0 | $0 | 1 | $200,612 | $-200,612 |
| Moore Erin | Interim PFO and PAO | 0 | $0 | 1 | $449,237 | $-449,237 |
| Parlavecchio Caryn | CHRO | 0 | $0 | 4 | $531,629 | $-531,629 |
| Ho Junlin | GENERAL COUNSEL | 0 | $0 | 3 | $653,153 | $-653,153 |
| Sacco Tracey | CHIEF COMMERCIAL OFFICER | 0 | $0 | 4 | $1.32M | $-1.32M |
| Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | 0 | $0 | 2 | $1.66M | $-1.66M |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 0 | $0 | 5 | $3.08M | $-3.08M |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | 0 | $0 | 5 | $3.61M | $-3.61M |
| Myles Edward H | COO & CFO | 0 | $0 | 6 | $12.77M | $-12.77M |
| AKKARAJU SRINIVAS | director | 0 | $0 | 1 | $34.39M | $-34.39M |
| Invus Public Equities, L.P. | 10 percent owner | 0 | $0 | 2 | $82.4M | $-82.4M |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Scholar Rock Holding Corporation have bought $0 and sold $141.87M worth of Scholar Rock Holding Corporation stock.
On average, over the past 5 years, insiders at Scholar Rock Holding Corporation have bought $23.78M and sold $30.23M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,189,781 shares for transaction amount of $15M was made by AKKARAJU SRINIVAS () on 2023‑10‑16.
| 2025-05-29 | Sale | Vaishnaw Akshay | President of R&D | 6,750 0.0071% | $29.72 | $200,612 | +8.47% | |
| 2025-05-29 | Sale | Gilman Michael | director | 3,375 0.0035% | $29.72 | $100,304 | +8.47% | |
| 2025-05-29 | Sale | FLIER JEFFREY S. | director | 6,075 0.0064% | $29.73 | $180,584 | +8.47% | |
| 2025-05-29 | Sale | Burow Kristina | director | 5,400 0.0057% | $29.72 | $160,511 | +8.47% | |
| 2025-05-29 | Sale | Reed Joshua | director | 5,400 0.0057% | $29.72 | $160,463 | +8.47% | |
| 2025-05-29 | Sale | Brudnick Richard | director | 6,075 0.0064% | $29.72 | $180,531 | +8.47% | |
| 2025-04-25 | Sale | Sacco Tracey | Chief Commercial Officer | 5,000 0.0053% | $32.83 | $164,131 | -5.36% | |
| 2025-03-24 | Sale | Moore Erin | Interim PFO and PAO | 13,564 0.014% | $33.12 | $449,237 | -8.37% | |
| 2025-03-24 | Sale | Sacco Tracey | Chief Commercial Officer | 6,500 0.0067% | $33.08 | $215,014 | -8.37% | |
| 2025-03-17 | Sale | Peng Katie | director | 1,006 0.0011% | $34.42 | $34,627 | -9.84% | |
| 2025-03-10 | Sale | Myles Edward H | COO & CFO | 142,292 0.1523% | $35.62 | $5.07M | -9.90% | |
| 2025-02-19 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 68,510 0.0741% | $37.40 | $2.56M | -14.42% | |
| 2025-02-18 | Sale | Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | 18,372 0.0195% | $36.83 | $676,622 | -11.94% | |
| 2025-02-18 | Sale | Ho Junlin | GENERAL COUNSEL | 5,742 0.0061% | $36.83 | $211,472 | -11.94% | |
| 2025-02-18 | Sale | Myles Edward H | COO & CFO | 7,809 0.0083% | $36.83 | $287,598 | -11.94% | |
| 2025-02-18 | Sale | Parlavecchio Caryn | CHRO | 5,296 0.0056% | $36.83 | $195,046 | -11.94% | |
| 2025-02-18 | Sale | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 4,135 0.0044% | $36.83 | $152,288 | -11.94% | |
| 2025-01-16 | Sale | Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | 22,308 0.0238% | $44.20 | $985,951 | -24.10% | |
| 2025-01-16 | Sale | Ho Junlin | GENERAL COUNSEL | 9,039 0.0096% | $44.20 | $399,498 | -24.10% | |
| 2025-01-16 | Sale | Myles Edward H | COO & CFO | 12,539 0.0134% | $44.20 | $554,189 | -24.10% |
| Invus Public Equities, L.P. | 10 percent owner | 9250005 9.7424% | $300.16M | 4 | 3 | +22.66% |
| AKKARAJU SRINIVAS | director | 5612896 5.9117% | $182.14M | 1 | 1 | +51.39% |
| Vaishnaw Akshay | President of R&D | 616205 0.649% | $20M | 0 | 1 | |
| Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | 311991 0.3286% | $10.12M | 0 | 3 | |
| Ho Junlin | GENERAL COUNSEL | 189295 0.1994% | $6.14M | 0 | 5 | |
| Parlavecchio Caryn | CHRO | 140258 0.1477% | $4.55M | 0 | 7 | |
| Myles Edward H | COO & CFO | 111345 0.1173% | $3.61M | 0 | 14 | |
| Qatanani Mo | CHIEF SCIENTIFIC OFFICER | 111084 0.117% | $3.6M | 0 | 9 | |
| Moore Erin | Interim PFO and PAO | 82609 0.087% | $2.68M | 0 | 1 | |
| Sacco Tracey | Chief Commercial Officer | 71750 0.0756% | $2.33M | 0 | 4 | |
| Marantz Jing L. | CHIEF MEDICAL OFFICER | 67200 0.0708% | $2.18M | 0 | 5 | |
| Gilman Michael | director | 55216 0.0582% | $1.79M | 0 | 4 | |
| Peng Katie | director | 30319 0.0319% | $983,851.55 | 0 | 1 | |
| FLIER JEFFREY S. | director | 24070 0.0254% | $781,071.50 | 0 | 4 | |
| Burow Kristina | director | 21071 0.0222% | $683,753.95 | 0 | 1 | |
| Reed Joshua | director | 15732 0.0166% | $510,503.40 | 0 | 1 | |
| Brudnick Richard | director | 15057 0.0159% | $488,599.65 | 0 | 1 | |
| Invus Public Equities Advisors, LLC | director | 8850005 9.3211% | $287.18M | 2 | 0 | +3.94% |
| Samsara BioCapital GP, LLC | 10 percent owner | 6788609 7.15% | $220.29M | 1 | 0 | +51.39% |
| SPRINGER TIMOTHY A | 3273519 3.4478% | $106.23M | 1 | 0 | +17.37% | |
| Nashat Amir | 2676311 2.8188% | $86.85M | 1 | 0 | +17.37% | |
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 2676311 2.8188% | $86.85M | 1 | 0 | +17.37% |
| Artal International S.C.A. | 10 percent owner | 450000 0.474% | $14.6M | 1 | 0 | +17.37% |
| Carven Gregory John | Head of Research | 32734 0.0345% | $1.06M | 0 | 2 |
$11,588,217 | 69 | 42.07% | $2.87B | |
$42,463,802 | 57 | 17.85% | $3.56B | |
$140,165,669 | 33 | 85.24% | $2.68B | |
$1,275,975,557 | 32 | 19.44% | $3.63B | |
$5,066,938 | 27 | 26.38% | $2.51B | |
$74,605,681 | 14 | 47.06% | $3.57B | |
$75,296,816 | 12 | 37.23% | $3.06B | |
$91,269,919 | 12 | 12.86% | $2.98B | |
Scholar Rock Holding Corporation (SRRK) | $70,151,579 | 12 | 22.57% | $3.08B |
$11,898,979 | 10 | 54.58% | $3.96B | |
$35,908,794 | 10 | 126.31% | $3.49B | |
$117,959,652 | 9 | -12.47% | $2.81B | |
$1,711,150 | 9 | 31.59% | $2.93B | |
$55,713,031 | 8 | -0.36% | $2.71B | |
$4,623,072 | 7 | 11.07% | $3.54B | |
$182,500,000 | 6 | 29.00% | $3.64B | |
$14,400,000 | 5 | 41.34% | $3.52B | |
$36,900,000 | 3 | -9.12% | $3.78B | |
$49,999,992 | 1 | 50.02% | $2.65B |
| Increased Positions | 131 | +56.22% | 14M | +13.79% |
| Decreased Positions | 99 | -42.49% | 8M | -8.26% |
| New Positions | 41 | New | 6M | New |
| Sold Out Positions | 31 | Sold Out | 2M | Sold Out |
| Total Postitions | 265 | +13.73% | 108M | +5.53% |
| Fmr Llc | $448,736.00 | 14.35% | 13.64M | +3M | +33.73% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $305,517.00 | 9.77% | 9.28M | +629,315 | +7.27% | 2024-12-31 |
| Siren, L.L.C. | $304,418.00 | 9.74% | 9.25M | -2M | -17.85% | 2024-12-31 |
| Blackrock, Inc. | $240,482.00 | 7.69% | 7.31M | +134,899 | +1.88% | 2025-03-31 |
| Samsara Biocapital, Llc | $184,720.00 | 5.91% | 5.61M | -1M | -17.32% | 2024-12-31 |
| Vanguard Group Inc | $156,108.00 | 4.99% | 4.74M | +708,817 | +17.57% | 2024-12-31 |
| Redmile Group, Llc | $149,737.00 | 4.79% | 4.55M | -688,956 | -13.15% | 2024-12-31 |
| Marshall Wace, Llp | $96,933.00 | 3.1% | 2.95M | +3M | +1,283.72% | 2024-12-31 |
| Polar Capital Holdings Plc | $89,132.00 | 2.85% | 2.71M | -232,301 | -7.9% | 2024-12-31 |
| Eventide Asset Management, Llc | $87,516.00 | 2.8% | 2.66M | +250,033 | +10.38% | 2024-12-31 |